Dr Richard Jones is an accomplished life sciences executive with 25 years experience in the pharmaceutical industry both in big pharma, biotech companies, contract organisation and with a strong background across multiple therapy areas. He has broad and extensive experience from business development, strategic alliances, M&As, R&D, early and late stage clinical development, general management and commercialisation. Dr Jones recently was appointed as CEO of BrYet Limited, a privately owned start up biotech company specialising in the field of nanotechnology. Prior to joining BrYet, Dr Jones served as SVP, Head of Europe for Akcea Therapeutics and prior to joining Akcea, served as CEO of Holostem Advanced Therapies, a cell and gene therapy developer/contract development and manufacturing organisation, and Akinion Pharmaceutical AB, where he focused on furthering the company’s clinical program in rare leukemias.
He previously served at Novartis and GSK as VP, Medicines Commercialization Leader Global Haematology at both companies. In these roles, Dr. Jones was responsible for the planning and execution of three global product launches, three regulatory submissions and initiation of several new drug development programs. Earlier at GSK, Dr. Jones served as Vice President, Global Commercial Leader for the company’s Rare Disease Unit, leading the strategy across multiple diseases and platforms. Dr. Jones joined GSK from Genzyme Corporation, where he served as Oncology & Transplant Portfolio Director, Global Oncology business. Prior to Genzyme, Dr. Jones worked as a Managing Consultant with MSI Consultancy and held various International and Therapy Area GM Project lead roles at Shire Plc.
Dr Jones holds a BSc (Hons) in Biochemistry and PhD in Molecular Oncology from University of Surrey.
Richard Buick has more than 19 years’ experience in the biopharmaceutical industry. After graduating with a 1st Class Honours degree in Genetics, he spent 4 years at Randox Laboratories, discovering novel antibodies for diagnostics from synthetic libraries. Richard joined Fusion Antibodies in 2002, where he was responsible for overseeing the Company’s Contract Research Services and production of all reagents required for the research and development of internal drug assets. Richard has a PhD from Queen’s University Belfast in Immunology. He joined the Company as a Director and was appointed CTO in 2011, managing all scientific projects and Fusion Antibodies’ patent portfolios. In addition, Richard has, since 2015, been appointed as a legal expert witness in a number of drug patent dispute cases.
Teresa Byrne has over eighteen years’ experience in the biopharmaceutical industry specifically in mammalian expression both stable and transient. Teresa holds a B.Sci (Hons) in Biochemistry from the National University of Ireland Galway, and a PhD in Biomedical Chemistry from Queens University Belfast.
Teresa joined Fusion Antibodies in 2003 focusing on the establishment and subsequent expansion of mammalian cell expression departments which have become a cornerstone of Fusion Antibodies core service offering. Teresa progressed her career from her initial role as a Senior Research Scientist role at Fusion to her latest appointment as Production Director in 2019.
James Fair has over ten years’ of experience working in the Bioscience sector. A mathematics graduate, James qualified as a chartered accountant in 1992, having trained with a Big Four firm. He has been head of finance with Fusion Antibodies for eight years on a secondment basis and joined the Company as a Director full time on 1 August 2017, where he is responsible for all aspects of financial management, including internal and external financial reporting. James has been involved in the growth of the business and previous raisings for the Company.
James’s previous experience has included senior management positions in internal audit, business and professional practice, where his recent experience was in advising and supporting start-up and spin-out companies from Northern Ireland entrepreneurs and local Universities.
Julie Gormley has over 15 years’ experience working within the biotech and pharma industry. She completed her PhD in protein directed evolution at the University of Nottingham in 2005 and started her career working as a Research Scientist and Senior Scientist at Fusion Antibodies before transitioning into Business Development. She continued her career in Business Development and Commercialisation taking positions at Redx Pharma, UK, and the University of Liverpool, UK. Julie returned to Fusion Antibodies in 2017 as a Business Development Director focussed on driving growth, with establishment of key accounts and collaborations to build long-term value for the company. Julie was appointed Commercial Senior Director in 2021.
Hugh Morgan has over 15 years of experience working in the drug discovery field. He completed his PhD in structural biology in 2007 at Edinburgh University. Hugh then completed five years as a post-doctoral research fellow in drug discovery, generating more than 20 publications, including first author publications in both Nature and PNAS. In 2012, he transitioned from academia to industry, focusing on a career in developing antibody therapeutics. He joined Fusion antibodies in 2016 as a team leader for the protein purification and analytics department. Hugh was appointed Director of Operations in 2019.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.